230 related articles for article (PubMed ID: 23996800)
1. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
[TBL] [Abstract][Full Text] [Related]
2. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.
Long PM; Tighe SW; Driscoll HE; Fortner KA; Viapiano MS; Jaworski DM
J Cell Physiol; 2015 Aug; 230(8):1929-43. PubMed ID: 25573156
[TBL] [Abstract][Full Text] [Related]
3. Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells.
Long PM; Tighe SW; Driscoll HE; Moffett JR; Namboodiri AM; Viapiano MS; Lawler SE; Jaworski DM
PLoS One; 2013; 8(11):e80714. PubMed ID: 24278309
[TBL] [Abstract][Full Text] [Related]
4. N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells.
Long PM; Moffett JR; Namboodiri AMA; Viapiano MS; Lawler SE; Jaworski DM
J Biol Chem; 2013 Sep; 288(36):26188-26200. PubMed ID: 23884408
[TBL] [Abstract][Full Text] [Related]
5. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
6. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Gong X; Schwartz PH; Linskey ME; Bota DA
Neurology; 2011 Mar; 76(13):1126-34. PubMed ID: 21346220
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Zhang D; Jing Z; Qiu B; Wu A; Wang Y
Oncol Rep; 2011 Oct; 26(4):901-8. PubMed ID: 21725605
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl l-aspartate and Triacetin modulate tumor suppressor MicroRNA and class I and II HDAC gene expression induce apoptosis in Glioblastoma cancer cells in vitro.
Mekala JR; Kurappalli RK; Ramalingam P; Moparthi NR
Life Sci; 2021 Dec; 286():120024. PubMed ID: 34626605
[TBL] [Abstract][Full Text] [Related]
9. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM
Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289
[TBL] [Abstract][Full Text] [Related]
10. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
11. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Joshi K; Banasavadi-Siddegowda Y; Mo X; Kim SH; Mao P; Kig C; Nardini D; Sobol RW; Chow LM; Kornblum HI; Waclaw R; Beullens M; Nakano I
Stem Cells; 2013 Jun; 31(6):1051-63. PubMed ID: 23404835
[TBL] [Abstract][Full Text] [Related]
12. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
[TBL] [Abstract][Full Text] [Related]
13. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
15. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.
Lamoral-Theys D; Le Mercier M; Le Calvé B; Rynkowski MA; Bruyère C; Decaestecker C; Haibe-Kains B; Bontempi G; Dubois J; Lefranc F; Kiss R
Neoplasia; 2010 Jan; 12(1):69-79. PubMed ID: 20072655
[TBL] [Abstract][Full Text] [Related]
16. EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Yu Q; Liu L; Wang P; Yao Y; Xue Y; Liu Y
Cell Cycle; 2017 Jun; 16(11):1085-1092. PubMed ID: 28436750
[TBL] [Abstract][Full Text] [Related]
17. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
[TBL] [Abstract][Full Text] [Related]
18. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
20. A safety trial of high dose glyceryl triacetate for Canavan disease.
Segel R; Anikster Y; Zevin S; Steinberg A; Gahl WA; Fisher D; Staretz-Chacham O; Zimran A; Altarescu G
Mol Genet Metab; 2011 Jul; 103(3):203-6. PubMed ID: 21474353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]